公开(公告)号：US20240262842A1

公开(公告)日：2024-08-08

申请号：US18557487

申请日：2022-04-27

申请人： Merck Sharp & Dohme LLC

发明人： Kazuaki SHIBATA ,  Hiroki Asakura ,  Kei AKEMOTO ,  Toshihiro SAKAMOTO ,  Hitomi KONDO ,  Tomohiro YAMAMOTO ,  Risako MIURA ,  Patrick SCHÖPF ,  Juan DEL POZO ,  George Madalin GIAMBUSU ,  Thomas H. GRAHAM ,  Yongxin HAN ,  Elisabeth T. HENNESSY ,  Anandan PALANI ,  Michael RYAN ,  David L. Sloman ,  Steven HOWARD

IPC分类号： C07D491/22 ,  A61K31/407 ,  A61K31/4188 ,  A61K31/437 ,  A61P35/00 ,  C07D471/16 ,  C07D487/16 ,  C07D498/06 ,  C07D498/16

CPC分类号： C07D491/22 ,  A61K31/407 ,  A61K31/4188 ,  A61K31/437 ,  A61P35/00 ,  C07D471/16 ,  C07D487/16 ,  C07D498/06 ,  C07D498/16

摘要： Compounds of Formula (I) or (Ia) or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or (Ia) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

公开(公告)号：US20230337537A1

公开(公告)日：2023-10-19

申请号：US17912871

申请日：2021-03-19

申请人： Merck Patent GmbH

发明人： Amir Hossain PARHAM

IPC分类号： H10K85/60 ,  C09K11/06 ,  C07F5/02 ,  C07D487/16 ,  C07D487/06 ,  C07D513/16 ,  C07D498/16 ,  C07D498/06 ,  C07D513/06

CPC分类号： H10K85/658 ,  C07D487/06 ,  C07D487/16 ,  C07D498/06 ,  C07D498/16 ,  C07D513/06 ,  C07D513/16 ,  C07F5/027 ,  C09K11/06 ,  H10K85/657 ,  H10K85/6572 ,  C09K2211/1018 ,  H10K50/121

摘要： Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic device.

公开(公告)号：US20230329106A1

公开(公告)日：2023-10-12

申请号：US18209996

申请日：2023-06-14

申请人： LG CHEM, LTD.

发明人： Minseung CHUN ,  Sang Young JEON ,  Tae Yoon PARK ,  Seongmi CHO

IPC分类号： H10K85/60 ,  C07D487/04 ,  C07D209/86 ,  C07D487/14 ,  C07D471/06 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D403/12 ,  C09K11/06 ,  C07C211/61 ,  C07D307/91 ,  C07D471/10 ,  C07D487/16 ,  C07D498/06

CPC分类号： H10K85/6572 ,  C07D487/04 ,  C07D209/86 ,  C07D487/14 ,  C07D471/06 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D403/12 ,  H10K85/615 ,  H10K85/622 ,  H10K85/626 ,  H10K85/633 ,  H10K85/636 ,  H10K85/654 ,  H10K85/657 ,  C09K11/06 ,  C07C211/61 ,  C07D307/91 ,  C07D471/10 ,  C07D487/16 ,  C07D498/06 ,  H10K50/11

摘要： The present specification relates to an organic light emitting element comprising: an anode; a cathode disposed opposite to the anode; and a light emitting layer disposed between the anode and the cathode, wherein the light emitting layer comprises: a host including a P-type host and an N-type host for generating an exciplex; and a phosphorescent dopant, and the host including the P-type host and the N-type host for generating an exciplex emits photoluminescence light having a longer wavelength than that emitted from each of the P-type host and the N-type host.

公开(公告)号：US11708377B2

公开(公告)日：2023-07-25

申请号：US17470608

申请日：2021-09-09

申请人： Oregon State University

发明人： Christopher M. Beaudry ,  Xuan Ju

IPC分类号： C07D498/06 ,  C07D491/153

CPC分类号： C07D498/06 ,  C07D491/153

摘要： Disclosed herein are embodiments of a compound having a Formula I




or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof.





Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.

公开(公告)号：US20230192719A1

公开(公告)日：2023-06-22

申请号：US18065868

申请日：2022-12-14

申请人： CANON KABUSHIKI KAISHA

发明人： HIROKAZU MIYASHITA ,  JUN KAMATANI ,  NAOKI YAMADA ,  HIRONOBU IWAWAKI ,  HIROKI OHRUI ,  YOSUKE NISHIDE

IPC分类号： C07D498/06 ,  H10K85/60 ,  C07D513/06 ,  C07D519/00 ,  C07D471/06 ,  C07D498/16 ,  C07D513/16 ,  C07D471/16 ,  C07F7/08 ,  H10K85/40 ,  H10K85/30 ,  H10K50/80

CPC分类号： C07D498/06 ,  H01L51/0071 ,  H01L51/0073 ,  C07D513/06 ,  C07D519/00 ,  C07D471/06 ,  H01L51/0072 ,  H01L51/0067 ,  H01L51/0074 ,  C07D498/16 ,  C07D513/16 ,  C07D471/16 ,  C07F7/0812 ,  H01L51/0094 ,  H01L51/0064 ,  H01L51/007 ,  H01L51/0085 ,  H01L51/52 ,  C07B2200/05

摘要： An organic compound represented by the formula [1]:




R1 to R19 are independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and a substituent, and R9 and R19 are optionally bonded together. When R9 and R19 are bonded together, the bonding is selected from the group consisting of direct bonding, bonding via an oxygen atom or a sulfur atom, and bonding via CR20R21. R20 and R21 independently have the same meaning as R1 to R19. X1 and X2 independently denote an oxygen atom, a sulfur atom, CR20R21, or a single bond. Ar denotes an aromatic hydrocarbon group or a heterocyclic group, n denotes an integer in the range of 0 to 2, and m denotes an integer in the range of 1 to 4. When n is 0, any one of R1 to R8 is directly bonded to any one of R9 to R19.

公开(公告)号：US20180331301A1

公开(公告)日：2018-11-15

申请号：US15539202

申请日：2015-11-24

申请人： Merck Patent GmbH

发明人： Amir Hossain PARHAM ,  Thomas EBERLE ,  Anja JATSCH ,  Tobias GROSSMANN ,  Jonas Valentin KROEBER

IPC分类号： H01L51/00 ,  C07D498/06 ,  C07D487/16 ,  C07D487/06 ,  C07D513/06 ,  C07D487/22

CPC分类号： H01L51/0072 ,  C07D487/06 ,  C07D487/16 ,  C07D487/22 ,  C07D498/06 ,  C07D513/06 ,  H01L51/0035 ,  H01L51/5056 ,  H01L51/5072 ,  H01L51/5096 ,  Y02E10/549

摘要： The present invention relates to heterocyclic compounds and electronic devices, in particular organic electroluminescent devices, containing these compounds.

公开(公告)号：US20180297983A1

公开(公告)日：2018-10-18

申请号：US15575583

申请日：2016-05-19

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

发明人： Dominique Amans ,  Stephen John Atkinson ,  Michael David Barker ,  Matthew Campbell ,  Hawa Diallo ,  Clement Douault ,  Neil Stuart Garton ,  John Liddle ,  Jessica Fanny Renaux ,  Robert John Sheppard ,  Ann Louise Walker ,  Christopher Roland Wellaway ,  David Matthew Wilson

IPC分类号： C07D401/14 ,  C07D498/04 ,  C07D405/14 ,  C07D413/14 ,  C07D403/14

CPC分类号： C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D498/04 ,  C07D498/06

摘要： Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

公开(公告)号：US20180222920A1

公开(公告)日：2018-08-09

申请号：US15802142

申请日：2017-11-02

申请人： Incyte Corporation

发明人： Andrew P. Combs ,  Richard B. Sparks

IPC分类号： C07D498/06

CPC分类号： C07D498/06

摘要： The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

公开(公告)号：US20180148461A1

公开(公告)日：2018-05-31

申请号：US15879619

申请日：2018-01-25

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Donald J.P. Pinto ,  James R. Corte ,  Wu Yang ,  William R. Ewing

IPC分类号： C07D519/00 ,  C07D487/08 ,  C07D498/08 ,  C07D471/08

CPC分类号： C07D519/00 ,  C07D471/06 ,  C07D471/08 ,  C07D487/06 ,  C07D487/08 ,  C07D498/06 ,  C07D498/08

摘要： The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US20180065983A1

公开(公告)日：2018-03-08

申请号：US15258175

申请日：2016-09-07

申请人： Genentech, Inc.

发明人： Marie-Gabrielle Braun ,  Keira Garland ,  Emily Hanan ,  Hans Purkey ,  Steven T. Staben ,  Robert Andrew Heald ,  Jamie Knight ,  Calum Macleod ,  Aijun Lu ,  Guosheng Wu ,  Siew Kuen Yeap

IPC分类号： C07D498/04 ,  A61K31/553 ,  A61K31/5383 ,  A61K31/498 ,  A61K31/4439 ,  A61K31/428 ,  A61K31/423 ,  A61K31/4196 ,  C07D491/044 ,  A61K45/06 ,  C07D519/00

CPC分类号： C07D498/04 ,  A61K31/4188 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5365 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06 ,  C07D491/044 ,  C07D498/06 ,  C07D519/00

摘要： Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.